In this study, we demonstrated for the first time that asperlin prevented HFD-induced obesity and alleviated hyperlipidemia. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.Īsperlin is a marine-derived fungal product possessing multiple properties such as antitumor, anti-inflammation and anti-atherosclerosis. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress. A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Hyperlipidemia and liver steatosis were also substantially ameliorated. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities.
0 kommentar(er)
